Latest news with #FSPKF
Business Insider
4 days ago
- Business
- Business Insider
Citi upgrades Fisher & Paykel Healthcare Corporation Limited (FSPKF) to a Hold
Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from Citi analyst Mathieu Chevrier today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: According to TipRanks, Chevrier is an analyst with an average return of -5.4% and a 40.30% success rate. Chevrier covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per Cochlear , and EBOS Group Limited. In addition to Citi, Fisher & Paykel Healthcare Corporation Limited also received a Hold from UBS's Marcus Curley in a report issued on May 29. However, on May 30, Morgan Stanley upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy. Based on Fisher & Paykel Healthcare Corporation Limited's latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $951.2 million and a net profit of $153.2 million. In comparison, last year the company earned a revenue of $815.8 million and had a net profit of $107.3 million
Business Insider
29-05-2025
- Business
- Business Insider
Fisher & Paykel Healthcare Corporation Limited (FSPKF) was downgraded to a Hold Rating at UBS
Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from UBS analyst Marcus Curley today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is ranked #9118 out of 9551 analysts. In addition to UBS, Fisher & Paykel Healthcare Corporation Limited also received a Hold from Morgan Stanley's David Bailey in a report issued on May 27. However, yesterday, Jefferies upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy.
Yahoo
28-05-2025
- Business
- Yahoo
Fisher & Paykel Healthcare Corp Ltd (FSPKF) Full Year 2025 Earnings Call Highlights: Robust ...
Operating Revenue: $2.02 billion, up 16% on FY24, 14% in constant currency. Net Profit After Tax: $377.2 million, up 43% on FY24, 30% in constant currency. Hospital Operating Revenue: $1.28 billion, up 18% on FY24, 16% in constant currency. Homecare Operating Revenue: $739.9 million, up 13% on FY24, 11% in constant currency. Gross Margin: 62.9%, increase of 181 basis points, 129 basis points in constant currency. Operating Margin: 25.2%, increase of 379 basis points, 260 basis points in constant currency. R&D Expenses: $227 million, 14% growth, 11% of revenue. SG&A Expenses: $534 million, increase of 8% in both reported and constant currency. Operating Cash Flow: $549 million, up 28% from last year. Capital Expenditure: $103 million, down from $339 million last year. Net Cash: $200.5 million as of March 31. Final Dividend: $0.24 per share, 2% increase from last year. Full-Year Dividend: $0.425 per share, up 2% from last year, 66% payout of full-year profit. Foreign Currency Impact: Positive impact of $39 million on NPAT compared to last year. Warning! GuruFocus has detected 11 Warning Signs with FSPKF. Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fisher & Paykel Healthcare Corp Ltd (FSPKF) reported a 16% increase in operating revenue, reaching $2.02 billion for the full year. Net profit after tax rose by 43% to $377.2 million, showcasing strong financial performance. The company successfully launched new products, including the Nova Nasal mask and Airvo 3, contributing to growth in both hospital and homecare segments. Gross margin improved by 181 basis points, driven by manufacturing and overhead efficiencies. Operating cash flow increased by 28% to $549 million, reflecting robust profit growth and efficient cash management. Global tariffs are expected to impact gross margin by approximately 75 basis points annually, posing a challenge to margin improvement. The company faces variability in hospital revenue due to seasonal respiratory hospitalizations, which could affect financial outcomes. Operating expenses grew by 10%, which, although expected, indicates rising costs that need to be managed. The OSA mask revenue growth slowed in the second half due to competitive pressures, highlighting market challenges. The company anticipates a longer timeline to achieve its target gross margin of 65% due to ongoing tariff impacts. Q: Can you provide insights into the revenue guidance for FY26, particularly regarding the hospital segment and new product contributions? A: Lewis Gradon, CEO, explained that all new products contribute to the revenue, typically impacting by 1% to 2% annually. Products like the Optiflow Switch and Airvo 3 are part of a long-term rollout strategy, contributing to the overall growth. Q: What factors contributed most to the gross margin expansion, and what should we expect for FY26? A: Lyndal York, CFO, noted that improvements in overhead efficiency and freight contributed significantly to the margin expansion. For FY26, a 100 basis points improvement in constant currency is expected, with freight remaining flat and overhead efficiency reducing in quantum. Q: How is the rollout and penetration of Airvo 3 progressing, particularly in the U.S.? A: Lewis Gradon, CEO, stated that Airvo 3 facilitates clinical practice changes, making it easier for hospitals to adopt. In the U.S., Airvo 3 accounts for about half of the current volume, and continued growth is expected. Q: Can you discuss the impact of tariffs on gross margins and any pricing strategies to mitigate this? A: Lewis Gradon, CEO, mentioned that tariffs could impact gross margins by 75 basis points annually. The company plans to offset this through continuous improvement efforts and routine pricing negotiations, aiming for a net 50 basis points improvement in constant currency. Q: What are the expectations for anesthesia consumables growth in FY26? A: Lewis Gradon, CEO, expects anesthesia consumables to grow by 30% to 40% in FY26, supported by ongoing investments in the sales force to match business growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
20-05-2025
- Business
- Business Insider
UBS Remains a Buy on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
UBS analyst Marcus Curley maintained a Buy rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is an analyst with an average return of -12.5% and a 44.16% success rate. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fisher & Paykel Healthcare Corporation Limited with a $24.95 average price target. FSPKF market cap is currently $12.8B and has a P/E ratio of 111.53. Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FSPKF in relation to earlier this year.
